Skip to content

Half-Dose Depot Triptorelin Versus Reduced-Dose Daily Buserelin

Half-Dose Depot Triptorelin Versus Reduced-Dose Daily Buserelin in a Long Protocol of Controlled Ovarian Stimulation for ICSI/ET

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00461916
Enrollment
182
Registered
2007-04-18
Start date
2005-05-31
Completion date
2006-12-31
Last updated
2007-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

half-dose depot triptorelin, reduced-dose daily buserelin, controlled ovarian stimulation, long protocol, ICSI

Brief summary

The purpose of this study is to determine whether half-dose depot triptorelin are as effective as reduced-dose daily buserelin in the controlled ovarian stimulation for intracytoplasmic sperm injection and embryo transfer

Detailed description

Significant doubts remain about which type of GnRH agonists \[GnRHa\] administration to be used in controlled ovarian stimulation \[COS\] cycles. The use of a single-dose depot long-acting GnRHa instead of a daily low dose preparation would be more comfortable for patients, however, inducing a profound pituitary desensitization, it increases the number of gonadotropin ampoules and the duration of the COS cycle without improving pregnancy rates or other clinical outcomes. Thus, some authors recommend a reduction of both dose and/or duration of GnRHa administration. Halving the dose of depot triptorelin, for instance, has been studied against its full dose administration since 1992 with rather similar clinical outcomes. Half-dose depot leuprolide acetate has also resulted in comparable clinical outcomes with standard daily injections in long GnRHa protocol. Reducing the daily doses of short acting GnRHa has been advocated to demonstrate equivalent results to standard doses. To our knowledge, however, the reduced daily doses have not been evaluated against half dose depot forms in long GnRHa protocols. Thus, we originally compared a half-dose depot triptorelin with reduced daily doses of short-acting buserelin in a long protocol for intracytoplasmic sperm injection and embryo transfer \[ICSI/ET\] cycles.

Interventions

DRUGHalf-Dose Depot Triptorelin
DRUGReduced-Dose Daily Buserelin

Sponsors

Tehran University of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
FEMALE
Age
No minimum to 35 Years
Healthy volunteers
No

Inclusion criteria

* Candidate for ICSI/ET * 35 years old or younger * Serum FSH less than 10 IU/l on day three of the previous menstrual cycle * No more than two previous IVF/ICSI attempts * No planned percutaneous epididymal sperm aspiration \[PESA\] * No planned testicular sperm extraction \[TESE\] * No known history or risk of severe hyperstimulation * No evidence of hydrosalpinx * No major systemic disease * No uterine abnormality * No previous ovarian surgery

Design outcomes

Primary

MeasureTime frame
Number of retrieved oocytes

Secondary

MeasureTime frame
Number of hMG ampoules
Number of follicles at hCG administration
Quality of oocytes
Quality of embryos
Poor response rate
Oocyte fertilization rate
Number of days of gonadotropin stimulation
Clinical pregnancy rate
Implantation rate
Biochemical pregnancy rate
Multiple pregnancy rate
Miscarriage rate
Ectopic pregnancy rate
Ineffective intervention rate

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026